Project Grant R03CA308475
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University a Project Grant of $640,775 under the Cancer Treatment Research program (CFDA 93.395) on June 22, 2026, with a completion date of May 31, 2031. The grant supports a co-clinical trial investigating the role of intratumoral bacteria in driving immunosuppression and immune checkpoint inhibitor (ICI) resistance in head and neck squamous cell carcinoma...
- Summary of Federal Project Grant Award Case Western Reserve University's Office of Research Administration received a $403,686 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) for the period July 1, 2026, through June 30, 2028. The award supports research to characterize IL-33-responsive mucosal cells and their role in colitis-associated cancer (CAC) development. The project addresses the critical gap in understanding how...
- Federal Project Grant Award Summary The National Cancer Institute awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University a Project Grant of $713,601 (awarded August 1, 2025; completion date July 31, 2030) under the Cancer Treatment Research program (CFDA 93.395) to investigate how homologous recombination (HR) DNA repair pathway mutations influence tumor immunity and immunotherapy efficacy. The research will characterize the mechanisms by which HR defects affect...
- Federal Grant Award Summary The National Cancer Institute awarded the Regents of the University of Michigan a $2.86 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop and validate a novel microbial-based therapeutic strategy targeting colibactin, a carcinogenic metabolite produced by pathogenic gut bacteria associated with colorectal cancer (CRC). The project, which commenced September 10, 2025, and extends through August 31, 2029, focuses on engineering...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $660,541 to The University of Texas MD Anderson Cancer Center for research under the Cancer Biology Research program (CFDA 93.396). The award, effective April 1, 2026, through March 31, 2031, supports fundamental research on the modulation of the tumor microenvironment by Fusobacterium nucleatum (FN) and co-infecting microbial species in colorectal cancer (CRC). The research addresses a critical...
- Federal Project Grant Award Summary The National Cancer Institute awarded $671,226 to the University of California, San Diego on May 15, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop engineered native bacteria-based therapies for colorectal cancer prevention and treatment. The project, with an ultimate completion date of April 30, 2031, focuses on creating a microbial platform utilizing host-derived E. coli strains that can durably colonize the gastrointestinal...
- Federal Grant Award Summary Cleveland Clinic Lerner College of Medicine of Case Western Reserve University received a $487,468 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, through August 31, 2030. The award supports fundamental research investigating the role of palmitoylation—a reversible lipid modification process—in melanoma lung metastasis and tumor progression. The research will examine how the...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $697,131 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. This fundamental research initiative addresses immune resistance mechanisms in colorectal cancer (CRC) by investigating the myeloid-stromal axis in the tumor microenvironment. The research will deliver scientific findings on how cancer-associated...
- Federal Project Grant Award Summary Award Details: Case Western Reserve University received a $630,108 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded March 13, 2026, with completion targeted for February 28, 2030. The research will be conducted in Cleveland, Ohio in affiliation with University Hospitals of Cleveland. Research Scope and Deliverables: This project develops and validates theranostic...
- Federal Project Grant Award Summary Cleveland Clinic Lerner College of Medicine of Case Western Reserve University received a $443,052 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) awarded August 1, 2026, with completion targeted for July 31, 2031. The grant funds fundamental cancer biology research investigating the role of WNK1 (With-No-Lysine Kinase 1) in glioblastoma progression and therapeutic resistance. The research...
Award Details:
The National Cancer Institute (NCI) awarded $157,000 in project grant funding (CFDA 93.395, Cancer Treatment Research) to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, effective July 1, 2026, through June 30, 2028. The research will be conducted in Cleveland, Ohio. Products and Services:
This project grant supports research to identify and characterize gut bacterial species that can modulate immune checkpoint molecule (ICM) expression—specifically PD-L1 and CD80—in colorectal cancer (CRC) tumors. The primary research deliverable involves integrating transcriptomic and phenotypic profiling within a bioengineered CRC-on-a-chip model to assess the ability of multiple bacterial species and strains to reduce ICM expression and enhance tumor immunogenicity. Preliminary findings indicate that Bifidobacterium adolescentis significantly reduces PD-L1 and CD80 expression in colorectal tumors. This research addresses a critical therapeutic gap, as approximately 85% of CRC patients present with mismatch repair-proficient, microsatellite-stable tumors that exhibit low immunogenicity and resistance to immune checkpoint inhibitor-based immunotherapy. The project aims to establish the scientific foundation for leveraging microbiome-based interventions to overcome immune resistance in CRC and render these tumors more responsive to cancer therapy.Summary of Federal Project Grant Award
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $157.0k | 6/23/26 |